Opinion|Videos|July 29, 2024
Safety Profile of Available Frontline Treatments LR-MDS
Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.
Advertisement
Episodes in this series
- Briefly comment on the safety profile of available frontline treatments for patients with LR-MDS.
- How would you mitigate those events in your practice?
- How does toxicities observedimpact your overall treatment selection for patients?
Advertisement
Related to this article
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
3
FDA Grants Fast Track Designation to Opamtistomig for Advanced Biliary Tract Cancer
4
Dr Hansen on the Integration of CAR T-Cell Therapy Into Earlier Myeloma Treatment Lines
5